Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [ <sup>18</sup>F]Flortaucipir and [ <sup>18</sup>F]Florbetapir Brain PET Studies

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Purpose

The simplified reference tissue model (SRTM) is commonly applied for the quantification of brain positron emission tomography (PET) studies, particularly because it avoids arterial cannulation. SRTM requires a validated reference region which is obtained by baseline-blocking or displacement studies. Once a reference region is validated, the use should be verified for each new subject. This verification normally requires volume of distribution ( V _T) of a reference region. However, performing dynamic scanning and arterial sampling is not always possible, specifically in elderly subjects and in advanced disease stages. The aim of this study was to investigate the use of non-invasive standardised uptake value (SUV) approaches, in comparison to V _T, as a verification of the previously validated grey matter cerebellum reference region for [ ¹⁸F]flortaucipir and [ ¹⁸F]florbetapir PET imaging in Alzheimer’s disease (AD) patients and controls.

Procedures

Dynamic 130-min [ ¹⁸F]flortaucipir PET scans obtained from nineteen subjects (10 AD patients) and 90-min [ ¹⁸F]florbetapir dynamic scans obtained from fourteen subjects (8 AD patients) were included. Regional V _T’s were estimated for both tracers and were considered the standard verification of the previously validated reference region. Non-invasive SUVs corrected for body weight (SUV _BW), lean body mass (SUL), and body surface area (SUV _BSA) were obtained by using later time intervals of the dynamic scans. Simulations were also performed to assess the effect of flow and specific binding (BP _ND) on the SUVs.

Results

A low SUV corresponded well with a low V _T for both [ ¹⁸F]flortaucipir and [ ¹⁸F]florbetapir. Simulation confirmed that SUVs were only slightly affected by flow changes and that increases in SUV were predominantly determined by the presence of specific binding.

Conclusions

In situations where dynamic scanning and arterial sampling is not possible, a low SUV _{(80–100 min)} for [ ¹⁸F]flortaucipir and a low SUV _{(50–70 min)} for [ ¹⁸F]florbetapir may be used as indication for absence of specific binding in the grey matter cerebellum reference region.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11307-020-01572-y.

Related collections

Most cited references 24

Record: found
Abstract: found
Article: not found

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

William E Klunk, Robert A Koeppe, Julie C Price … (2015)

Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission tomography), and now with F-18-labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there has been considerable variability in the exact numbers reported as quantitative outcome measures of tracer retention. In some cases this is as trivial as the choice of units, in some cases it is scanner dependent, and of course, different tracers yield different numbers. Our working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (≤ 45 years) and typical Alzheimer's disease patients. The units of this scale have been named "Centiloids." Basically, we describe a "standard" method of analyzing PiB PET data and then a method for scaling any "nonstandard" method of PiB PET analysis (or any other tracer) to the Centiloid scale. Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

0 comments Cited 358 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.

Alexander Hammers, Richard Allom, Matthias J. Koepp … (2003)

Probabilistic atlases of neuroanatomy are more representative of population anatomy than single brain atlases. They allow anatomical labeling of the results of group studies in stereotaxic space, automated anatomical labeling of individual brain imaging datasets, and the statistical assessment of normal ranges for structure volumes and extents. No such manually constructed atlas is currently available for the frequently studied group of young adults. We studied 20 normal subjects (10 women, median age 31 years) with high-resolution magnetic resonance imaging (MRI) scanning. Images were nonuniformity corrected and reoriented along both the anterior-posterior commissure (AC-PC) line horizontally and the midsagittal plane sagittally. Building on our previous work, we have expanded and refined existing algorithms for the subdivision of MRI datasets into anatomical structures. The resulting algorithm is presented in the Appendix. Forty-nine structures were interactively defined as three-dimensional volumes-of-interest (VOIs). The resulting 20 individual atlases were spatially transformed (normalized) into standard stereotaxic space, using SPM99 software and the MNI/ICBM 152 template. We evaluated volume data for all structures both in native space and after spatial normalization, and used the normalized superimposed atlases to create a maximum probability map in stereotaxic space, which retains quantitative information regarding inter-subject variability. Its potential applications range from the automatic labeling of new scans to the detection of anatomical abnormalities in patients. Further data can be extracted from the atlas for the detailed analysis of individual structures. Copyright 2003 Wiley-Liss,Inc.

0 comments Cited 232 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.

Paul E Kinahan, Andrew Fletcher (2010)

The use of standardized uptake values (SUVs) is now common place in clinical 2-deoxy-2-[(18)F] fluoro-D-glucose (FDG) position emission tomography-computed tomography oncology imaging and has a specific role in assessing patient response to cancer therapy. Ideally, the use of SUVs removes variability introduced by differences in patient size and the amount of injected FDG. However, in practice there are several sources of bias and variance that are introduced in the measurement of FDG uptake in tumors and also in the conversion of the image count data to SUVs. In this article the overall imaging process is reviewed and estimates of the magnitude of errors, where known, are given. Recommendations are provided for best practices in improving SUV accuracy. Copyright © 2010 Elsevier Inc. All rights reserved.

0 comments Cited 179 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Sandeep S. V. Golla: s.golla@amsterdamumc.nl

Journal

Journal ID (nlm-ta): Mol Imaging Biol

Journal ID (iso-abbrev): Mol Imaging Biol

Title: Molecular Imaging and Biology

Publisher: Springer International Publishing (Cham )

ISSN (Print): 1536-1632

ISSN (Electronic): 1860-2002

Publication date (Electronic): 14 January 2021

Publication date PMC-release: 14 January 2021

Publication date (Print): 2021

Volume: 23

Issue: 4

Pages: 550-559

Affiliations

[1 ]GRID grid.12380.38, ISNI 0000 0004 1754 9227, Radiology and Nuclear Medicine, Amsterdam UMC, , Vrije Universiteit Amsterdam, ; De Boelelaan 1117, Amsterdam, The Netherlands

[2 ]GRID grid.12380.38, ISNI 0000 0004 1754 9227, Alzheimer Center and Department of Neurology, Amsterdam UMC, , Vrije Universiteit Amsterdam, ; De Boelelaan 1117, Amsterdam, The Netherlands

[3 ]GRID grid.12380.38, ISNI 0000 0004 1754 9227, Epidemiology & Biostatistics, Amsterdam UMC, , Vrije Universiteit Amsterdam, ; De Boelelaan 1117, Amsterdam, The Netherlands

Author information

Bart M. de Vries https://orcid.org/0000-0002-6421-8303

Article

Publisher ID: 1572

DOI: 10.1007/s11307-020-01572-y

PMC ID: 8277631

PubMed ID: 33443720

SO-VID: a22de2b1-0808-4829-b93a-939c0382cdf9

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 22 September 2020

Date revision received : 20 November 2020

Date accepted : 16 December 2020

Funding

Funded by: FundRef http://dx.doi.org/10.13039/100014392, Avid Radiopharmaceuticals;

Custom metadata

ScienceOpen disciplines: Molecular biology

Keywords: standardised uptake value,[18f]flortaucipir,[18f]florbetapir,srtm,alzheimer’s disease

Data availability:

ScienceOpen disciplines: Molecular biology

Keywords: standardised uptake value, [18f]flortaucipir, [18f]florbetapir, srtm, alzheimer’s disease